NASDAQ:BIOL BIOLASE (BIOL) Stock Price, News & Analysis → The Single Biggest Breakthrough of the Decade (From Porter & Company) (Ad) Free BIOL Stock Alerts $0.14 0.00 (-0.48%) (As of 10:14 AM ET) Add Compare Share Share Today's Range$0.14▼$0.1550-Day Range$0.14▼$0.1952-Week Range$0.13▼$10.31Volume108,757 shsAverage Volume3.80 million shsMarket Capitalization$4.83 millionP/E RatioN/ADividend YieldN/APrice Target$0.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get BIOLASE alerts: Email Address BIOLASE MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside175.5% Upside$0.40 Price TargetShort InterestBearish6.55% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.74 out of 5 stars 3.3 Analyst's Opinion Consensus RatingBIOLASE has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBIOLASE has only been the subject of 2 research reports in the past 90 days.Read more about BIOLASE's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.55% of the float of BIOLASE has been sold short.Short Interest Ratio / Days to CoverBIOLASE has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BIOLASE has recently increased by 25.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBIOLASE does not currently pay a dividend.Dividend GrowthBIOLASE does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIOL. Previous Next 2.5 News and Social Media Coverage News SentimentBIOLASE has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for BIOLASE this week, compared to 1 article on an average week.Search Interest8 people have searched for BIOL on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added BIOLASE to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BIOLASE insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.27% of the stock of BIOLASE is held by insiders.Percentage Held by InstitutionsOnly 8.79% of the stock of BIOLASE is held by institutions.Read more about BIOLASE's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of BIOLASE is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BIOLASE is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BIOLASE's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About BIOLASE Stock (NASDAQ:BIOL)BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.Read More BIOL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOL Stock News HeadlinesJune 14 at 4:40 AM | americanbankingnews.comBIOLASE (NASDAQ:BIOL) Research Coverage Started at StockNews.comJune 5, 2024 | americanbankingnews.comBIOLASE (NASDAQ:BIOL) Coverage Initiated at StockNews.comMay 14, 2024 | markets.businessinsider.comWhat Wall Street expects from Biolase's earningsMay 14, 2024 | msn.comBIOLASE, Inc. (NASDAQ:BIOL) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comQ1 2024 BIOLASE Inc Earnings CallMay 14, 2024 | finance.yahoo.comBiolase Inc (BIOL) Q1 2024 Earnings Call Transcript Highlights: Strategic Gains Amidst Economic ...May 12, 2024 | msn.comBiolase Q1 2024 Earnings PreviewMay 1, 2024 | au.finance.yahoo.comBIOLASE, Inc. (BIOL) stock historical prices & data – Yahoo FinanceApril 26, 2024 | markets.businessinsider.comMama’s Creations: Strong Financial Performance and Growth Potential Justify Buy RatingApril 17, 2024 | msn.comBIOLASE (BIOL) Price Target Decreased by 19.68% to 11.45March 29, 2024 | markets.businessinsider.comCelsius Holdings: Strong Buy on Robust Finances and Global Expansion StrategyMarch 24, 2024 | marketwatch.comBiolase Shares Jump 27% After Upbeat 2024 Revenue GuidanceMarch 23, 2024 | seekingalpha.comBIOLASE, Inc. (BIOL) Q4 2023 Earnings Call TranscriptMarch 23, 2024 | markets.businessinsider.comBiolase’s Strong Q4 Performance and Positive 2024 Outlook Affirm Buy RatingMarch 23, 2024 | finance.yahoo.comBIOLASE, Inc. (NASDAQ:BIOL) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | markets.businessinsider.comWhy BIOLASE Shares Are Surging FridayMarch 22, 2024 | finance.yahoo.comQ4 2023 BIOLASE Inc Earnings CallMarch 21, 2024 | benzinga.comRecap: Biolase Q4 EarningsMarch 21, 2024 | sfgate.comBiolase: Q4 Earnings SnapshotMarch 20, 2024 | benzinga.comEarnings Preview For BiolaseFebruary 23, 2024 | markets.businessinsider.comMaxim Group Reaffirms Their Buy Rating on Biolase (BIOL)February 22, 2024 | finanznachrichten.deBIOLASE, Inc.: Biolase Launches State-of-the-Art All-Tissue Laser System To Accelerate Adoption of Lasers in DentistryFebruary 22, 2024 | finance.yahoo.comBiolase Launches State-of-the-Art All-Tissue Laser System To Accelerate Adoption of Lasers in DentistryFebruary 21, 2024 | msn.comThe Toothbrush Storage Idea That Saves Valuable Counter Space In The BathroomFebruary 20, 2024 | finanznachrichten.deBIOLASE, Inc.: Biolase Announces First Quarter 2024 Webinar Series 'Lets Talk Dental'See More Headlines Receive BIOL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/14/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Dental equipment & supplies Sub-IndustryN/A Current SymbolNASDAQ:BIOL Previous SymbolNASDAQ:BLTI CUSIPN/A CIK811240 Webwww.biolase.com Phone(949) 361-1200Fax949-273-6677Employees157Year FoundedN/APrice Target and Rating Average Stock Price Target$0.40 High Stock Price Target$0.40 Low Stock Price Target$0.40 Potential Upside/Downside+176.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($14.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,630,000.00 Net Margins-43.56% Pretax Margin-43.46% Return on Equity-1,782.73% Return on Assets-57.55% Debt Debt-to-Equity Ratio34.06 Current Ratio1.17 Quick Ratio0.64 Sales & Book Value Annual Sales$49.16 million Price / Sales0.10 Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-2.06Miscellaneous Outstanding Shares33,400,000Free Float33,305,000Market Cap$4.83 million OptionableNot Optionable Beta0.74 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. John R. Beaver (Age 63)President, CEO & Director Comp: $377.53kMs. Jennifer Bright (Age 52)Chief Financial Officer Comp: $355.98kMr. Steven Sandor (Age 43)Chief Operating Officer Comp: $336.39kMr. Michael C. Carroll (Age 52)Corporate Secretary Key CompetitorsSonendoNYSE:SONXSmileDirectClubNASDAQ:SDCCQBiomericaNASDAQ:BMRASmileDirectClubNASDAQ:SDCDENTSPLY SIRONANASDAQ:XRAYView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 131,248 shares on 5/20/2024Ownership: 0.430%View All Institutional Transactions BIOL Stock Analysis - Frequently Asked Questions Should I buy or sell BIOLASE stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BIOL shares. View BIOL analyst ratings or view top-rated stocks. What is BIOLASE's stock price target for 2024? 2 Wall Street research analysts have issued 12-month target prices for BIOLASE's stock. Their BIOL share price targets range from $0.40 to $0.40. On average, they predict the company's share price to reach $0.40 in the next twelve months. This suggests a possible upside of 175.5% from the stock's current price. View analysts price targets for BIOL or view top-rated stocks among Wall Street analysts. How have BIOL shares performed in 2024? BIOLASE's stock was trading at $1.1220 at the beginning of 2024. Since then, BIOL stock has decreased by 87.1% and is now trading at $0.1452. View the best growth stocks for 2024 here. Are investors shorting BIOLASE? BIOLASE saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 2,100,000 shares, an increase of 25.7% from the May 15th total of 1,670,000 shares. Based on an average daily trading volume, of 4,790,000 shares, the days-to-cover ratio is currently 0.4 days. Approximately 6.6% of the shares of the stock are short sold. View BIOLASE's Short Interest. When is BIOLASE's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our BIOL earnings forecast. How were BIOLASE's earnings last quarter? BIOLASE, Inc. (NASDAQ:BIOL) issued its earnings results on Monday, May, 13th. The medical technology company reported ($0.36) earnings per share for the quarter. The medical technology company earned $10.13 million during the quarter. BIOLASE had a negative net margin of 43.56% and a negative trailing twelve-month return on equity of 1,782.73%. When did BIOLASE's stock split? BIOLASE's stock reverse split on the morning of Friday, July 28th 2023. The 1-100 reverse split was announced on Friday, July 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What guidance has BIOLASE issued on next quarter's earnings? BIOLASE updated its FY 2024 earnings guidance on Monday, May, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $52.0 million-$53.0 million, compared to the consensus revenue estimate of $51.5 million. What is John R. Beaver's approval rating as BIOLASE's CEO? 4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com. John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend. What other stocks do shareholders of BIOLASE own? Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Biocept (BIOC), Magnachip Semiconductor (MX), Fluidigm (FLDM), Matinas BioPharma (MTNB), MicroVision (MVIS), Acasti Pharma (ACST), Bionano Genomics (BNGO) and Genius Brands International (GNUS). Who are BIOLASE's major shareholders? BIOLASE's stock is owned by a variety of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.43%). Insiders that own company stock include Education Foundation Schuler, John R Beaver, John R Beaver and Jonathan T Md Lord. View institutional ownership trends. How do I buy shares of BIOLASE? Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BIOL) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BIOLASE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BIOLASE With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.